Olutasidenib Capsules for Acute Myeloid Leukemia - A Comprehensive Overview

Overview:

Olutasidenib should be taken twice a day on an empty stomach. Consuming the medication at least one hour before or two hours after a meal is recommended. Some possible side effects of this medication include nausea, fatigue, fever, constipation, diarrhea, abnormal results of liver function tests, and alterations in certain blood tests. Serious adverse events that must be treated promptly include differentiation syndrome and hepatotoxicity. Avoid breastfeeding during and for at least two weeks after treatment with Olutasidenib.On December 1st, 2022, the United States Food and Drug Administration (USFDA) approved Olutasidenib capsules for acute myeloid leukemia (AML). Olutasidenib FDA-approval capsules are effective in AML management.

Drug Group:

Olutasidenib is an IDH1 inhibitor and is used for recurring or refractory forms of acute myeloid leukemia, or AML. It impacts the cancer cell by restricting its proliferation. Olutasidenib versus Ivosidenib, both these drugs belong to the same drug group, but Olutasidenib has a longer duration of response than Ivosidenib.

Dosages:

It is suggested to be taken at a dose of 150 mg (milligrams) twice a day until the disease worsens or the toxicity becomes unbearable. Take it on an empty stomach at least one hour before or two hours after a meal.

For Patients:

How Is Acute Myeloid Leukemia (AML) Treated?

Unchecked expansion of immature myeloid cells characterizes acute myeloid leukemia (AML), one of the most prevalent forms of aggressive bone marrow cancers. The leukemic cells remain confined to the bone marrow in various genetic anomalies that underlie the heterogeneity of AML. Recently, major genetic abnormalities in AML have been identified to impact both prognosis and therapy, including drugs targeted to FLT3 and IDH1/2.

Acute myeloid leukemia is treated with intensive induction chemotherapy, consolidation therapy, or stem cell transplantation. Cytarabine and chemotherapy based on anthracyclines are part of the standard treatment. However, currently, treatments cure only around 30 to 35 percent of patients. With new therapy, results have been better, including targeted medicines like FLT3 inhibitors and IDH neoenzyme inhibitors. The treatment goals for older adults include effective, controllable regimens and reducing drug resistance. Precision medicine and targeted medications offer hope for better AML care. For elderly or debilitated patients, less intensive treatments and palliative care are available.

How Does Olutasidenib Capsules Work?

Olutasidenib capsules intervene by inhibiting the product of a mutant isocitrate dehydrogenase-1 (IDH1) gene, thereby causing the proliferation of cancer cells to slow down or even stop. It kills the cells through this inhibition mechanism. In Outasidenib synthesis, the IDH1 inhibitor is designed to focus specifically on the AML with the IDH1 mutation, thus giving the disease a targeted therapeutic strategy.

What Are the Benefits of Olutasidenib Capsules Used for Acute myeloid leukemia (AML)?

Olutasidenib provides an alternative for relapsed or refractory mIDH1-AML patients, offering the option of targeted mIDH1 therapies with higher complete response rates and longer response duration. Olutasidenib's median duration of response was 25.9 months, with a 35 percent rate of complete remission or full remission with partial hematologic recovery. Besides granting transfusion independence in 34 percent of patients, Olutasidenib had a manageable safety profile and achieved long-lasting remissions in patients with mIDH1 R/R AML.

What Must the Patient Inform the Doctor Before Taking Olutasidenib Capsules?

Patients who are hypersensitive to Olutasidenib or other drugs, have liver or renal insufficiency, are pregnant, plan to conceive, or are nursing should communicate the same to the physician before the use of Olutasidenib capsules. Any prescription and over-the-counter drugs, vitamins, nutritional supplements, and herbal preparations should be informed to the patient's physician. In addition, patients on Olutasidenib should avoid St. John Wort (a herb) during treatment. All severe side effects associated with Olutasidenib can be reported to the FDA through the patient or physician.

What Are the Side Effects of Olutasidenib Capsules?

• Nausea.

• Constipation.

• Diarrhea.

• Vomiting.

• Stomach pain.

• Mouth sores.

• Abnormal liver function tests.

• Changes in blood tests.

• Liver problems.

• Differentiation syndrome (severe reactions to drugs used for AML).

For Doctors:

Description:

• Chemical Name: (S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino.

• Type: Isocitrate dehydrogenase-1 (IDH1) inhibitor-1-methyl2-carbonitrile-6-oxo-1,6-dihydropyridine

• Molecular Formula: C18H15ClN4O2.

• Molecular Weight: 354.79 g/mol.

Physical Form:

• Appearance: White to off-white to brown powder.

• Solubility: At pH 1.2 and 7.4 formulations, it is practically insoluble in aqueous solutions

• The dosage form is hard gelatin capsules for oral administration. The components of the capsule are 150 mg of Olutasidenib.

• Excipients:Sodium croscarmellose,Magnesium stearate and Microcrystalline cellulose.

• Shell Ingredients of the capsule are gelatin and titanium dioxide of titanium.

• Ink components are Ferroferric acid, Glycol propylene, and Shellac.

Dosage Forms:

The available dosage form of Olutasidenib capsules is 150 mg.

Dosage and Administration:

The usual adult dose of 150 mg should be given orally twice daily, and Olutasidenib should be given on an empty stomach at least one hour before a meal or two hours after a meal. If a dose is missed, do not take extra capsules; continue with the regular dosing schedule. Routine medical follow-ups are mandatory during treatment. Olutasidenib is continued until disease progression or unacceptable toxicity occurs.

Indications:

Adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH1 mutation susceptible to inhibition, as detected by an approved test from the FDA, can be treated with the IDH1 inhibitor Olutasidenib.

Contraindications:

Olutasidenib capsules are not indicated in patients with a liver problem history. It is vital to inform the physician if they are pregnant.

Warnings and Precautions:

Among the subjects with relapsed or refractory AML who received Olutasidenib, based on clinical trials, 16 percent suffered from differentiation syndrome; severe forms were seen in eight percent, and one percent died because of the disease. The disease is fatal; it manifests due to rapid myeloid cell differentiation and proliferation. Some symptoms include leukocytosis, dyspnea, pulmonary infiltrates, renal impairment, fever, edema, and weight gain. 76 percent of the 25 affected patients responded after a change in therapy. From day one to eighteen months after the initiation of Olutasidenib, differentiation syndrome can occur with or without leukocytosis. If suspected, discontinue the drug for at least three days and initiate systemic corticosteroids such as Dexamethasone. Consider hydroxyurea if there is leukocytosis. As very early discontinuation may lead to relapse,

An elevation of bilirubin, alkaline phosphatase, and liver enzymes, such as ALT and AST, was indicative of drug-related hepatotoxicity. Clinical studies showed that hepatotoxicity occurred in 23 percent of R/R AML patients, of whom 13 percent were severe (grades three or four). In one case of combination therapy in which Olutasidenib and Azacitidine-an unapproved combination-were used together, one patient died from drug-induced liver injury. After beginning treatment, hepatotoxicity typically starts 1.2 months later (from day 1 to 17.5 months) and resolves in 12 days (from day 1 to 17 months).

What Are the Adverse Reactions of Olutasidenib Capsules?

Abdominal pain, oral ulcers, abnormal laboratory blood tests, arthralgia or myalgia, rash, dyspnea, fatigue, liver injury, or biliary ductal dilatation. Differentiation syndrome, which includes fever, cough, edema, weight gain, and decreased urine output, might occur even within a range of 18 months from the initiation of treatment. Other 3-4 grade adverse events were elevations in aspartate and alanine aminotransferases.

What Are the Pharmacological Aspects of Olutasidenib Capsules?

1. Mechanism of Action: Olutasidenib is a small-molecule inhibitor of mutant isocitrate dehydrogenase-1. Vulnerable IDH1 mutations in AML patients are those that cause an increased level of 2-hydroxyglutarate (2-HG) in leukemia cells and whose activities are predicted either by clinically meaningful remissions at the approved dose of Olutasidenib or inhibition of mutant IDH1 enzymatic activity at concentrations of Olutasidenib that can be achieved at the approved dose as determined with validated methods. Among them, the most frequent mutations are R132H and R132C substitutions in AML patients.

The mutant IDH1 R132H, R132L, R132S, R132G, and R132C proteins were inhibited in vitro by Olutasidenib; neither wild-type IDH1 nor modified IDH2 proteins were inhibited. Reduced 2-HG levels in both in vitro and in vivo xenograft models result from Olutasidenib suppression of mutant IDH1.

2. Pharmacodynamics: Decrease of 2-HG Plasma Concentration: Pre-dose mean percent decrease: 59.1 percent (122 percent CV) Cycle 2: Patients with AML and IDH1 mutations have a decrease that is maintained throughout treatment.

• Differentiation Syndrome: The relationship is that increased exposures to Olutasidenib are associated with a greater risk of differentiation syndrome.

• Increase of QTc Interval: The largest mean increase of 33 patients was with single and multiple doses when on fasting - 6.2 msec; Upper 90 percent CI = 9.7 msec.

• Food Effects: Eating versus fasting, greater QT prolongation is expected.

• Limitations of the Assessment: Because higher doses were not studied, the clinical significance of a larger QTc interval at higher exposures of Olutasidenib was not established.

3. Pharmacokinetics: Steady State Concentrations: AUC0-12-h, ss 43,050 ng·h/mL (34.0percent CV).Cmax, ss 3,573 ng/mL (45.6percent CV).At 14 days, a steady state was achieved.

• Dose-Dependent Relationship: Over the 100 to 300 mg dose range, Cmax (maximum concentration) and AUC (area under the curve) increase less than proportionately. The accumulation ratio is 7.7 to 9.5.

• Absorption: Following a single dose of 150 mg, the Tmax is approximately four hours (range: one to eight hours).

• Food's Impact: Cmax rises by 191 percent and AUCinf increases by 83 percent when administered with a high-fat meal.

• Distribution: The apparent volume of dispersion is 319 L (28.1 percent CV). About 93 percent are bound to plasma proteins.

• Elimination: Half-life (t½): about 67 hours (CV = 51.2percent).

• Apparent oral clearance (CL/F) is four liters per hour (L/h) (60.5 percent CV).

• Metabolism: About 90 percent is metabolized by CYP3A4.The contributions from the CYP2C8, CYP2C9, CYP1A2, and CYP2C19 were all minor.

• Excretion: Around 35 percent remained unchanged, and 75 percent were recovered in feces.

• Urine recovered about 17 percent (1 percent remained unchanged).

Drug Interactions:

• Alfentanil.

• Amobarbital.

• Apalutamide.

• Armodafinil.

• Belzutifan.

• Bexarotene.

• Bosentan.

• Butabarbital.

• Butalbital.

• Capivasertib.

• Carbamazepine.

• Cenobamate.

• Clonidine.

• Colchicine.

• Cyclosporine.

• Dabrafenib.

• Dihydroergotamine.

• Disopyramide.

• Efavirenz.

• Elacestrant.

• Elagolix.

• Encorafenib.

• Enzalutamide.

• Ergotamine.

• Eslicarbazepine acetate.

• Ethosuximide.

• Etrasimod.

• Etravirine.

• Everolimus.

• Fentanyl.

• Fentanyl iontophoretic transdermal system.

• Fentanyl transdermal.

• Fentanyl transmucosal.

• Fosphenytoin.

• Fruquintinib.

• Ivosidenib.

• Lenacapavir.

• Leniolisib.

• Lorlatinib.

• Lumacaftor.

• Mavacamten.

• Midazolam.

• Mitapivat.

• Mitotane.

• Modafinil.

• Nafcillin.

• Nirogacestat.

• Omaveloxolone.

• Pacritinib.

• Palovarotene.

• Pentobarbital.

• Pexidartinib.

• Phenobarbital.

• Phenytoin.

• Pimozide.

• Pirtobrutinib.

• Praziquantel.

• Primidone.

• Quinidine.

• Quinine.

• Quizartinib.

• Repotrectinib.

• Rifabutin.

• Rifampin.

• Rifapentine.

• Sirolimus.

• Sotorasib.

• St John's Wort.

• Tacrolimus.

• Telotristat ethyl.

• Triazolam.

• Warfarin.

• Zanubrutinib.

• Zuranolone.

Use in Specific Populations:

• Pregnancy: The use of Olutasidenib in pregnancy may result in harm to the developing fetus. Data regarding the use of Olutasidenib in pregnant women is nonexistent for drug toxicity risk evaluation. In studies considered Olutasidenib-treated pregnant rats and rabbits, embryo-fetal loss was observed.

• Lactation: The excretion and effects of Olutasidenib and its metabolites in human milk on a child who is breastfed, as well as the effect on milk supply, are unknown. Exclusive breastfeeding is not recommended during treatment or two weeks after discontinuation of the drug because many drugs are excreted in human milk and can cause adverse reactions in a child.

• Administration in Pediatrics: Olutasidenib 's efficacy and safety in pediatric patients have not been demonstrated.

• Geriatrics: Of the 153 patients with relapsed or refractory AML included in the trial, 76 percent were at least 65 years of age, and 31 percent were 75 years of age or older. Although no significant differences in treatment efficacy were observed between younger and older patients, hepatotoxicity and hypertension were more common among those patients ≥ 65 years of age.

• Renal Impairment: No dosage adjustment is required for patients with mild to moderate renal impairment (creatinine clearance 30 to <90 mL/min (milliliters per minute). Patients on dialysis or with severe renal impairment do not have a defined dose.

• Hepatic Impairment: For mild to moderate hepatic impairment, no dose adjustment is needed; however, close monitoring for differentiation syndrome is recommended.

Clinical Trials:

Olutasidenib clinical trial studies are as follows:

For people who had previously been treated or who did not respond to therapy for gliomas with an IDH1 R132X mutation, we proved the efficacy of Olutasidenib with a 48 percent disease control rate. The recommended dose of the drug was 150 mg twice a day, and the drug was well tolerated. There were raised aspartate and alanine aminotransferase levels as the adverse effects. In patients with IDH1-mutated acute myeloid leukemia, Olutasidenib had a median response duration of 25.9 months and a complete remission rate of 35 percent. Adverse effects included leukopenia, asthenia, and vomiting.